In AD, complement C3 may reflect stage-associated biomarker changes in AD [31], and the presence of APOE-ε4 has been associated with elevated C3 levels, resulting in elevated Alzheimer’s neurodegeneration, noting that amyloid has a regulating effect on the complement system and is linked to subsequent tau protein pathology [32]. This evidence concerns the gene MAPT and Alzheimer disease.